Microbiome Movement

Concerto Biosciences 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐅𝐢𝐫𝐬𝐭 𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐧𝐭 𝐃𝐨𝐬𝐞𝐝 𝐰𝐢𝐭𝐡 𝐋𝐢𝐯𝐞 𝐁𝐢𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐄𝐍𝐒-𝟎𝟎𝟐 𝐢𝐧 𝐏𝐡𝐚𝐬𝐞 𝟏 𝐓𝐫𝐢𝐚𝐥 𝐟𝐨𝐫 𝐀𝐭𝐨𝐩𝐢𝐜 𝐃𝐞𝐫𝐦𝐚𝐭𝐢𝐭𝐢𝐬 𝐊𝐞𝐲 𝐈𝐧𝐟𝐨: - ENS-002 is a three-strain #LBP targeting 𝘚. 𝘢𝘶𝘳𝘦𝘶𝘴 - 𝘚. 𝘢𝘶𝘳𝘦𝘶𝘴 is a key driver of skin #inflammation - Hopefully, by addressing a #microbiome deficiency underlying atopic dermatitis, ENS-002 can offer a novel route to longer-lasting relief and fewer side effects than traditional treatments like steroids and immunosuppressants. 𝐓𝐫𝐢𝐚𝐥 𝐃𝐞𝐬𝐢𝐠𝐧: - Enrolling approx. 9 participants across 3 cohorts of increasing dose concentration and dose frequency. - Primary endpoints: safety & tolerability - Secondary endpoints: ability of ENS-002 to control 𝘚. 𝘢𝘶𝘳𝘦𝘶𝘴 abundance and address atopic dermatitis 𝐖𝐡𝐚𝐭'𝐬 𝐍𝐞𝐱𝐭? Concerto anticipates being able to report safety and preliminary proof of mechanism data in 2025. Link to article: https://lnkd.in/egzVx_fg

𝐆𝐮𝐭 𝐌𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐦𝐞 𝐓𝐫𝐚𝐧𝐬𝐩𝐥𝐚𝐧𝐭 𝐓𝐫𝐢𝐚𝐥 𝐟𝐨𝐫 𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧'𝐬: 𝐀 𝐍𝐞𝐰 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫 𝐢𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 A groundbreaking clinical trial in Japan is exploring the potential of gut microbiome transplants to treat Parkinson's disease. By restoring a healthier gut environment, researchers hope to improve treatment outcomes and potentially even uncover new insights into the disease's underlying mechanisms. This aligns with the insights being shared at the 𝐌𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐦𝐞 𝐌𝐨𝐯𝐞𝐦𝐞𝐧𝐭 𝐄𝐮𝐫𝐨𝐩𝐞 𝐒𝐮𝐦𝐦𝐢𝐭, where we will discuss the role of microbiota in Alzheimer's disease. Key findings include: - 𝐆𝐮𝐭 𝐌𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐭𝐚 𝐂𝐨𝐦𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧: The specific bacteria in our gut can significantly impact the development and progression of neurodegenerative diseases. - 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦𝐬: Dysfunctional gut microbiota may contribute to these conditions through inflammation, immune system imbalances, and even neurotransmitter production. - 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥: Identifying unique microbial signatures could revolutionize early diagnosis and personalized treatment for neurodegenerative diseases. The clinical trial in Japan, along with the leading research being presented at the summit, highlights the promising potential of targeting the gut microbiome to address neurodegenerative disorders. This approach offers a new avenue for developing innovative therapies and improving the lives of millions affected by these debilitating conditions. Link to article: https://lnkd.in/dqSaUe3F #GutMicrobiome #NeurodegenerativeDiseases #ParkinsonsDisease #AlzheimersDisease #MicrobiomeMovementEurope #MedicalResearch #Healthcare #Innovation #MicrobiomeMovement

New study reveals the gut microbiome's central role in #autoimmune diseases! 🦠🔍 Researchers have identified significant overlaps in the microbial signatures of SLE and IBD, suggesting shared mechanisms. This groundbreaking discovery opens doors for targeted therapies based on gut bacteria. Key findings: - Distinct #microbial profiles for each autoimmune condition, highlighting the microbiome's diverse roles. - Interactions between gut #bacteria and host signaling pathways, providing potential therapeutic targets. This study paves the way for #personalizedmedicine and innovative treatments for autoimmune diseases. With an everchanging landscape, you can expect to uncover novel #mechanistic data for various disease types, even beyond the gut, at the 9th Annual #MicrobiomeMovement Europe Summit. Message me for more info. Link to article: https://lnkd.in/dcupvVzV

Real World Study of Recurrent Clostridioides difficile Therapy Demonstrates Efficacy, Safety. Ferring Pharmaceuticals shares results from its outpatient study examining its treatment, Rebyota (#LBP), for the prevention of recurrence. Key notes: - 59 patients completed the 8-week follow up period. 75% had no #CDI recurrence - No adverse events reported with treatment apart from minor leakage during administration in 4 patients (6.2%) Rebyota, whilst gaining FDA approval in the United States, hasn't yet received market access in Europe perhaps due to more stringent regulations around this novel modality and from my conversations, has been making #investment challenging. There will be no better opportunity than the 9th Annual Microbiome Movement Europe Summit to tackle investor engagement with our panel of experts at SOSV, M Ventures , Seventure Partners, Corundum Systems Biology, & EIT Health, gain regulatory insights on new EU SoHO Regulation and Proposed Pharmaceutical Legislation by Céline Druart, and trigger the potential for investment in 2025. View the full agenda: https://ter.li/2s1of8 #MicrobiomeMovement #Regulation #LBP #FMT #Probiotics #Microbiome Pop me a message if you have any questions, or email me at: mehmet.gul@hansonwade.com Fionnuala Lane Eris Ejupi Kelly Cassidy

Clinical #Microbiome News: What a week it's been for microbiome drug development in Europe... - 𝐌𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐭𝐢𝐜𝐚 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐅𝐢𝐫𝐬𝐭 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐃𝐨𝐬𝐞𝐝 𝐢𝐧 𝐢𝐭𝐬 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐏𝐡𝐚𝐬𝐞 𝟏𝐛 𝐓𝐫𝐢𝐚𝐥, 𝐌𝐄𝐋𝐎𝐃𝐘-𝟏 𝐨𝐟 𝐌𝐁𝟎𝟗𝟕 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐦𝐞 𝐂𝐨-𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐌𝐞𝐥𝐚𝐧𝐨𝐦𝐚 Link to article: https://lnkd.in/eN4UHxMu - 𝐌𝐚𝐚𝐓 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐬 𝐑𝐞𝐜𝐫𝐮𝐢𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐢𝐭𝐬 𝐀𝐑𝐄𝐒 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐓𝐫𝐢𝐚𝐥 𝐟𝐨𝐫 𝐌𝐚𝐚𝐓𝟎𝟏𝟑 𝐭𝐨 𝐓𝐫𝐞𝐚𝐭 𝐀𝐜𝐮𝐭𝐞 𝐆𝐫𝐚𝐟𝐭-𝐯𝐞𝐫𝐬𝐮𝐬-𝐇𝐨𝐬𝐭 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 Link to article: https://lnkd.in/efShNj7W Hear from both Microbiotica and MaaT Pharma at the Microbiome Movement Summit in Europe this January to de-risk your jump to the clinic, tackle challenges in investor engagement, and take home learnings from leading organizations driving the charge in microbiome therapeutic development.

I'm proud to announce I will be leading the Partnerships for our Microbiome Movement EU Summit taking place between 28 - 30 January, 2025 in Barcelona, Spain! The European microbiome industry has seen a lot of recent clinical excitement including: - Infant Bacterial Therapeutics AB phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality - Microbiotica in the U.K. secured additional funding to complete the COMPOSER-1 phase 1 study to treat #UlcerativeColitis and is expecting results at the end of 2025 - Exeliom Biosciences in France is running 3x trials and dosing #LBP in combination with nivolumab in #immunooncology and is expecting results in the next 2 years 𝗛𝗢𝗪𝗘𝗩𝗘𝗥: LBPs are the main area of focus for microbiome drug developers, and as an emerging modality & with no approvals and difficulty of market access for US-approved products in Europe, the regulatory landscape is uncertain and making #investment is challenging. We will be bringing all the right senior stakeholders under one roof (Investors, large pharma, leading LBP developers, academic innovators of microbial modalities, and consumer-focused microbiome industry members) at the start of the year to trigger the potential for investment. For more information, view the website here: https://ter.li/54oiq3 Alternatively, share this with your network, and drop me a message if you're interested in learning more. Thanks everyone - looking forward to this one! Best, Mehmet 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 | 𝗕𝗶𝗼𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗶𝗻𝗴 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲 𝗠𝗼𝘃𝗲𝗺𝗲𝗻𝘁 𝗛𝗮𝗻𝘀𝗼𝗻 𝗪𝗮𝗱𝗲 𝗚𝗿𝗼𝘂𝗽 #Microbiome #MicrobiomeMovement